RS 42358-197

a 5-hydroxytryptamine-3 receptor ligand; structure given in first source

Also Known As:

(3H)-RS-42358-197; (S)-N-(1-azabicyclo(2.2.2)oct-3-yl)-2,4,5,6-tetrahydro-1H-benzo(de)isoquinolin-1-one hydrochloride; RS-42358-197; 1H-Benz(de)isoquinolin-1-one, 2-(1-azabicyclo(2.2.2)oct-3-yl)-2,4,5,6-tetrahydro-, monohydrochloride, (S)-

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Bridged-Ring Heterocyclic Compounds
  - Heterocyclic Bridged Bicyclo Compounds
    - RS 42358-197: 1
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoquinolines: 34
      - Tetrahydroisoquinolines: 44
        RS 42358-197: 1

Related Diseases

Vomiting

08/01/1993 - "RS 42358-197, administered orally, also afforded protection against cisplatin-induced emesis in ferrets. "
08/01/1993 - "When tested at maximally effective doses against cisplatin-induced emesis in dogs, RS 42358-197 had a longer duration of antiemetic activity (> 6 h) than ondansetron (2 h). "
08/01/1993 - "In dogs, RS 42358-197, administered either intravenously or orally, dose-dependently inhibited the emesis induced by cisplatin, actinomycin and cyclophosphamide, but not that induced by apomorphine. "

Related Drugs and Biologics

1.	Cisplatin (Platino)
2.	Ondansetron (Zofran)
3.	Dactinomycin (Actinomycin)
4.	Cyclophosphamide (Cytoxan)
5.	Apomorphine
6.	Antiemetics